RealTime Dynamix™: Crohn’s Disease Q2 2017

Spherix Global Insights has just released the second quarter results of an independent survey regarding the evolving practice patterns in the management of Crohn's disease (CD) in which US gastroenterologists (n=103) project significant gains for Janssen’s Stelara over the next six months. Click the button below to view highlights from the cardiology and nephrology perspective [...]

RealTime Dynamix: Psoriasis Q2 2017

While AbbVie’s Humira and Amgen’s Enbrel have borne the brunt of the IL-17 assault, Janssen’s Stelara has been buffered thus far. However, future projections indicate a flattening of the brand and further penetration of the IL-17 class. Just published RealTime Dynamix: Psoriasis Q2 2017 from Spherix Global Insights provides key insights on the shifting PsO [...]

RealTime Dynamix™: Hyperkalemia Q2 2017

With the introduction of Relypsa’s Veltassa in the beginning of 2016 and new competitors such as AstraZeneca/ZS Pharma’s ZS-9 potentially coming into play, RealTime Dynamix: Hyperkalemia provides a detailed and timely look at how the hyperkalemia market is evolving with these new therapeutic options. Click the button below to view highlights from the cardiology and [...]

RealWorld Dynamix™: Biologic Switching in IBD 2017

According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to 2016. Furthermore, switching patterns have changed dramatically with the recent introduction of Stelara. [...]

RealWorld Dynamix™: Biologic and Otezla Switching in PsA 2017

Spherix Global Insights has released the 2017 update of RealWorld Dynamix: PsA based on analysis of 1,008 PsA patient charts. The large scale chart audit was completed by about 200 rheumatologists and focuses on patients that have been switched between biologic brands and/or Otezla during the past three months. In addition to comparisons from the [...]